Advances in Hematology最新文献

{"title":"Real-World Outcomes of Venetoclax and Azacitidine in Hospitalized Patients With Acute Myeloid Leukemia: A Retrospective Study at a Tertiary Care Center.","authors":"Mallory Pane, Durga Bhavani Bandi, Andrew Whiteley, Anushah Mirza, Zachary Gopin, Andrew Irion, Sharon Park","doi":"10.1155/ah/5707397","DOIUrl":"https://doi.org/10.1155/ah/5707397","url":null,"abstract":"<p><p>Venetoclax plus azacitidine improves survival in older or unfit patients with newly diagnosed acute myeloid leukemia (AML), as demonstrated in the VIALE-A trial. ² However, real-world data in hospitalized patients-particularly those with secondary AML or adverse-risk mutations-remain limited. We conducted a retrospective study of exclusively hospitalized patients with treatment-naïve AML who completed at least one full 28-day cycle of azacitidine and venetoclax at Baylor University Medical Center between October 2019 and October 2024, with the aim of evaluating outcomes at a clinically relevant treatment inflection point. Risk stratification was performed using ELN 2022 criteria, and safety was assessed using CTCAE v5.0. Fifty-six patients met inclusion criteria (median age 71 years); 51.8% had secondary AML, and 53.7% had adverse-risk disease. Among 43 evaluable patients, the composite complete remission (CRc) rate after one cycle was 55.8%. Median overall survival (OS) was 17.6 months. Patients with TP53 mutations had significantly shorter median OS (3.8 months) compared with those without TP53 mutations (20.2 months). Common grade ≥ 3 toxicities included leukopenia (67.8%) and febrile neutropenia (57.6%). By focusing on patients who completed an initial treatment cycle, this study provides conditional survival estimates that may inform decisions regarding continuation of therapy. Despite the predominance of secondary and adverse-risk AML in this cohort, OS was comparable to that observed in VIALE-A, supporting the effectiveness of azacitidine plus venetoclax in hospitalized AML patients ineligible for intensive chemotherapy.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"5707397"},"PeriodicalIF":0.0,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Castleman Disease in Tunisia: A Multicenter Clinical, Prognostic, and Therapeutic Study.","authors":"Tayssir Ben Achour, Syrine Sassi, Aida Khadar, Wafa Skouri, Mariem Borgi, Maysem Jridi, Arfaoui Bilel, Aydi Zohra, Adaily Najeh, Amri Raja, Ben Abdelhafidh Nadia, Ben Abdelghni Khaoula, Ben Fraj Fatma, Ben Hssine Lamia, Boussema Fatma, Daada Syrine, Guediche Nour El Houda, Ines Chelly, Jebri Meriem, Smiti Monia","doi":"10.1155/ah/1623836","DOIUrl":"10.1155/ah/1623836","url":null,"abstract":"<p><strong>Introduction: </strong>Castleman disease is an uncommon benign lymphoproliferative condition that includes diverse clinical, biochemical, and histological variations, each characterized by unique prognoses and therapeutic approaches. The aim of our study was to characterize the clinical and paraclinical features, as well as the management approaches, of Castleman disease in the Tunisian population.</p><p><strong>Methods: </strong>We conducted a multicenter study including patients with a histologically confirmed diagnosis of Castleman disease who were followed in the Internal Medicine departments of various hospitals across Tunisia between 2000 and 2024.</p><p><strong>Results: </strong>Sixteen patients (55.2%) with multicentric Castleman disease and 13 patients (44.8%) with the unicentric form were included. The most frequent initial manifestations were lymphadenopathy (69%), mass (20%), fever (26.7%), and weight loss and fatigue (56.7%). HHV-8 tested positive in 10.7%, while 3.6% of patients had autoantibodies. Hyaline-vascular (53.6%), plasmacytic (32.1%), and mixed (14.3%) subtypes were diagnosed, with a distinct plasmacytic predominance among multicentric types. Following total surgical resection, 14 patients (48.3%) experienced immediate radiological and clinical remission. On the other hand, systemic therapy was required for patients with multicentric types. In total, 12 patients (44.4%) experienced full remission, (14.8%) remained stable, and (3.7%) continued to progress despite treatment.</p><p><strong>Conclusion: </strong>With a significant percentage of multicentric forms and a low HHV-8 seropositivity rate, our Tunisian study validates the various manifestations of Castleman disease.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"1623836"},"PeriodicalIF":0.0,"publicationDate":"2026-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhagic Cystitis in Patients Who Underwent Allogeneic Stem Cell Transplantation (2012-2025): A Single-Center Experience.","authors":"Khanh Ba Nguyen, Binh Thi Thanh Vo, Nhung Thi Nguyen, Thanh Ha Nguyen","doi":"10.1155/ah/4650693","DOIUrl":"10.1155/ah/4650693","url":null,"abstract":"<p><strong>Introduction: </strong>Hemorrhagic cystitis (HC) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT), especially in cases with haploidentical donors. Our study aimed to determine the incidence and analyze the risk factors associated with HC in patients undergoing allogeneic HSCT.</p><p><strong>Subjects and methods: </strong>This retrospective, cross-sectional study analyzed data from 343 patients who underwent allogeneic HSCT between January 2012 and June 2025 at our institution. The research variables included clinical characteristics, conditioning regimens, BK virus (BKV) status, and transplant outcomes.</p><p><strong>Results: </strong>The overall incidence of HC was 18.4% (63 out of 343 patients), with severe cases (Grades 3-4) comprising 9.4%. The median onset was 33 days posttransplantation, with a median duration of 40 days. BKV was detected in the urine of 19.9% of the patients, among whom 15.2% exhibited high viral loads. Multivariate Cox regression analysis identified three independent risk factors: malignant disease (hazard ratio [HR] = 4.212; <i>p</i> = 0.046), posttransplant severe infection (HR = 1.793; <i>p</i> = 0.033), and the use of posttransplant cyclophosphamide (PTcy) (HR = 3.404; <i>p</i> < 0.001). Regarding prognosis, the presence of HC did not significantly affect the 5-year overall survival (OS) probability (67.1% vs. 65.7% in the non-HC group, <i>p</i> = 0.921). However, patients with Grades 3-4 HC exhibited a significantly lower 5-year OS than those with Grades 1-2 (49.6% versus 86.6%, <i>p</i> = 0.007).</p><p><strong>Conclusion: </strong>HC is a prevalent complication of allogeneic HSCT, often presenting late and closely associated with malignancies, severe infections, and PTcy protocols. The severity of HC is a crucial determinant of survival outcomes, necessitating proactive preventive strategies and timely interventions to enhance the patient's prognosis.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"4650693"},"PeriodicalIF":0.0,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13584321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Hypomethylating Agents for Higher-Risk Myelodysplastic Syndromes: Report From the Nationwide Multicenter Thai MDS Study.","authors":"Theerin Lanamtieng, Chantana Polprasert, Pimjai Niparuck, Phatsorn Choksomnuk, Thanawat Rattanathammethee, Wasithep Limvorapitak, Kannadit Prayongratana, Rattapan Lamool, Archrob Khuhapinant, Weerapat Owattanapanich, Pisa Phiphitaporn, Kanchana Chansung, Suporn Chuncharunee","doi":"10.1155/ah/2732324","DOIUrl":"10.1155/ah/2732324","url":null,"abstract":"<p><p>Hypomethylating agents (HMAs) are the standard of care for higher-risk myelodysplastic syndromes (MDSs); however, their accessibility remains limited. This retrospective multicenter cohort study aimed to evaluate the real-world overall survival (OS) of HMAs compared to best-available treatments (BATs) in newly diagnosed higher-risk MDS in Thailand. Higher-risk MDS was defined by a Revised International Prognostic Scoring System (IPSS-R) score > 3.5. Data were extracted from the MDS registry of multicenter hospitals in Thailand from 2013 to 2023. Patients who underwent hematopoietic stem cell transplantation were excluded. A total of 155 patients were included, with a median age of 70 years and a male predominance. The median follow-up time was 36 months. Of these, 86 patients (55.5%) received BATs, while 69 patients (44.5%) were treated with HMAs. HMAs were found to significantly improve OS compared to BATs (log-rank test: <i>p</i> = 0.03), with a median OS of 15 months versus 6 months, respectively. Multivariable Cox regression analysis revealed that HMAs were associated with a decreased risk of death (hazard ratio: 0.58, 95% CI, 0.38-0.89, <i>p</i> = 0.01), while age and high- and very high-risk IPSS-R were identified as poor prognostic factors. This study underscores the real-world effectiveness of HMAs for higher-risk MDS in Thailand.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"2732324"},"PeriodicalIF":0.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary Proteomic Signatures in Sickle Cell Disease: Search for Biomarkers Associated With Underlying Molecular Pathways.","authors":"Vera Hoving, Hans Wessels, Jolein Gloerich, Miranda van Berkel, Albertine E Donker, Dorine W Swinkels, Saskia E M Schols","doi":"10.1155/ah/8684436","DOIUrl":"https://doi.org/10.1155/ah/8684436","url":null,"abstract":"<p><p>Identifying urinary biomarkers of sickle cell disease (SCD) may provide insights into disease mechanisms and support improved disease monitoring. In this pilot study, we analyzed the urinary proteome of 32 SCD patients (children and adults, steady state, and various genotypes) and 19 healthy controls using mass spectrometry-based proteomics. A total of 2263 proteins were detected, of which 978 were consistently quantified across groups. Ninety proteins showed differential abundance between SCD patients and controls, with 26 upregulated and 64 downregulated in SCD. Upregulated proteins included those associated with cellular stress response (e.g., DNA damage-inducible 1 homolog 2) and immune activation, whereas proteins involved in hemoglobin clearance and mitochondrial metabolism were downregulated, consistent with hemolysis and mitochondrial dysfunction. These findings suggest that urinary proteomics can capture systemic processes relevant to SCD pathophysiology. Despite the small and heterogeneous cohort, this study highlights candidate urinary biomarkers and molecular pathways that warrant validation in larger, stratified cohorts to assess their potential for disease monitoring.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"8684436"},"PeriodicalIF":0.0,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578929/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apixaban in Abdominal Transplantation: An Antithrombotic Stewardship Assessment.","authors":"Diana Kwiatkowski, Tania Ahuja, Roshani Patolia, Dawn M Pluckrose, David Green, Srijana Jonchhe","doi":"10.1155/ah/5894289","DOIUrl":"10.1155/ah/5894289","url":null,"abstract":"<p><strong>Background: </strong>Apixaban is a direct oral anticoagulant (DOAC) that is widely used in the general population; however, its use in solid organ transplant (SOT) recipients has not been extensively studied. Although there is interest in DOACs as the preferred oral anticoagulants in SOT recipients due to their favorable pharmacokinetic properties, there remain concerns for the optimal dose in the setting of organ dysfunction, at the time of engraftment, and for use for off-label indications such as graft thrombosis (GT).</p><p><strong>Objective: </strong>To assess \"real-world\" apixaban utilization in abdominal SOT recipients at a large academic medical center.</p><p><strong>Design: </strong>This was a single-center, observational, retrospective cohort study of 79 adult patients from January 2020 to August 2022 who received apixaban for any indication postabdominal transplant.</p><p><strong>Methods: </strong>All adult patients, ≥ 18 years of age, who received apixaban for any indication post kidney, liver, simultaneous liver-kidney (SLK), or simultaneous pancreas-kidney (SPK) transplant were included. Electronic health records were retrospectively reviewed for patient demographics, past medical history, and apixaban characteristics, including indication, dose, frequency, and the use of parenteral anticoagulation lead-in for acute thrombosis. The primary outcome was the incidence of thromboembolic events. Secondary outcomes included any bleeding events. In addition, adherence to package label dosing recommendations, based on indication of anticoagulation, was evaluated.</p><p><strong>Results: </strong>Among the 79 patients included, 51 (65%) were kidney, 18 (23%) were liver, 7 (9%) were SPK, and 3 (4%) were SLK transplant recipients. The most common indications for apixaban use were acute venous thromboembolism (VTE) (<i>n</i> = 33, 42%), stroke prevention with atrial fibrillation (AF) (<i>n</i> = 18, 23%), and treatment of GT (<i>n</i> = 13, 17%). The primary outcome of the incidence of any thromboembolic event was 3.8% (<i>n</i> = 3), which occurred at a median of 304 (IQR 168-309) days after apixaban initiation.</p><p><strong>Conclusions: </strong>Apixaban dosing was consistent with labeled dosing for the majority of the cohort for labeled indications, and the observed incidence of thromboembolic events in this cohort was low, with no excess identified relative to published literature. Our data support the use of apixaban for stroke prevention in AF or treatment of VTE or GT in patients who have received an abdominal transplant; however, risk factors for bleeding events, specifically in those with GT, should be further explored.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"5894289"},"PeriodicalIF":0.0,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13504357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Associated With Mortality in Diffuse Large B-Cell Lymphoma (DLBCL) With Disseminated Intravascular Coagulation (DIC): A National Inpatient Sample Analysis.","authors":"Safia Ansari, Kristy Bono, Berk Madendere, Anand Shah, Joshua Kra","doi":"10.1155/ah/8956944","DOIUrl":"10.1155/ah/8956944","url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Hematologic malignancies are known precipitants of disseminated intravascular coagulation (DIC), and the coexistence of these conditions is associated with poor outcomes; however, large-scale data specifically examining concurrent DLBCL and DIC are limited. We performed a retrospective cohort study using the National Inpatient Sample (NIS) to evaluate in-hospital mortality among adult hospitalizations with DIC and/or DLBCL identified using ICD-10 codes. Adults aged ≥ 18 years with a diagnosis of DLBCL and/or DIC were included. In-hospital mortality among patients with concurrent DLBCL and DIC was 54.1%, significantly higher than mortality observed in patients with either condition alone (<i>p</i> < 0.001). In multivariable analysis restricted to patients with both DLBCL and DIC, independent predictors of increased mortality included HIV/AIDS (aOR 4.266, 95% CI: 1.886-9.649; <i>p</i> < 0.001), septic shock (aOR 3.201, 95% CI: 2.305-4.443; <i>p</i> < 0.001), mechanical ventilation (aOR 2.948, 95% CI: 2.175-3.995; <i>p</i> < 0.001), vasopressor use (aOR 2.759, 95% CI: 1.789-4.255; <i>p</i> < 0.001), chronic kidney disease (aOR 2.523, 95% CI: 1.596-3.989; <i>p</i> < 0.001), acute kidney injury (aOR 1.884, 95% CI: 1.347-2.637; <i>p</i> < 0.001), Black race (aOR 2.221, 95% CI: 1.418-3.477; <i>p</i> < 0.001), and Asian or Pacific Islander race (aOR 2.383, 95% CI: 1.329-4.271; <i>p</i> = 0.004) compared to White patients. Bleeding events, thromboembolic complications, stem cell transplantation, and CAR-T therapy were not independently associated with mortality. These findings demonstrate that among patients with DLBCL, the development of DIC is associated with markedly elevated in-hospital mortality, driven predominantly by critical illness, organ dysfunction, and comorbidity burden rather than bleeding or thrombosis alone. Racial disparities in outcomes were independently observed after adjusting for illness severity and comorbidities, warranting further investigation. Early recognition of DIC in patients with DLBCL and aggressive management of systemic complications, particularly septic shock, respiratory failure, and renal dysfunction, may help mitigate disease severity and improve outcomes.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"8956944"},"PeriodicalIF":0.0,"publicationDate":"2026-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13478723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Pathobiology of Anaplastic Large Cell Lymphoma\".","authors":"","doi":"10.1155/ah/9754703","DOIUrl":"https://doi.org/10.1155/ah/9754703","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1155/2010/345053.].</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"9754703"},"PeriodicalIF":0.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13415744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Induction Toxicities in Childhood Acute Lymphoblastic Leukaemia in Ghana.","authors":"Lily Gloria Tagoe, Emmanuella Amoako, Ernestina Schandorf, Lorna A Renner, Catherine Segbefia, Kokou Amegan-Aho, Jennifer Welbeck, Yvonne Dei-Adomakoh","doi":"10.1155/ah/5787036","DOIUrl":"10.1155/ah/5787036","url":null,"abstract":"<p><strong>Introduction: </strong>Due to limited supportive care, low- and middle-income countries balance delivering intensive, curative chemotherapy with the risk of treatment-related toxicity. Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer, and induction is the highest risk period for morbidity and mortality. The study describes induction toxicities among children with ALL at Korle Bu Teaching Hospital, Ghana.</p><p><strong>Methods: </strong>This hospital-based cohort study involved children aged 1-17 years newly diagnosed with ALL from August 2021 to January 2023. Demographic, clinical and laboratory data were recorded. Descriptive statistics (median [interquartile range]) were used to summarise continuous variables. Frequency and percentages were used to describe categorical variables. Toxicities were graded using the Common Terminology Criteria for Adverse Events, Version 5.0.</p><p><strong>Results: </strong>Thirty-one children were included. Median age was 5 years (interquartile range [IQR]: 3-10 years). All 31 had at least one induction toxicity of any grade, and 29 (93.4%) had at least one severe (Grade ≥ 3). The most common toxicities were anaemia, thrombocytopenia, sepsis, febrile neutropenia, mucositis and hypertension; bleeding, acute pancreatitis, seizures and hepatotoxicity were less common. Induction mortality rate was 19.3%. There was no association found between age, sex, initial white cell count, treatment protocol and development of any severe toxicity.</p><p><strong>Conclusion: </strong>Severe induction toxicities were common in our cohort with unacceptably high mortality, underscoring the need to prioritise enhanced bedside clinical monitoring for hypertension, improved access to blood products and optimal infection prevention and control practices. Further research exploring the relationship between induction toxicities and patient outcomes is essential.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"5787036"},"PeriodicalIF":0.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.","authors":"M Di Cecca, Bongarzoni V, Garzia M, Fazio F, Tomarchio V, Barilà G, Liberatore C, Rago A, Rossini B, Rocco S, Pisani F, De Padua L, Fiori L, Tafuri M T, Anaclerico B, Cardarelli L, Scomazzon E, Fioritoni F, Caravita Di Torritto T, Quinto A M, Palmieri S, Lamanda M, Tamburini A, Piciocchi A, Petrucci M T, Rigacci L, Annibali O","doi":"10.1155/ah/5597825","DOIUrl":"10.1155/ah/5597825","url":null,"abstract":"<p><p>The COVID-19 pandemic posed significant challenges for patients with hematological malignancies, including multiple myeloma (MM), who experienced increased hospitalization and mortality rates due to frailty and immune suppression. This retrospective, multicenter study aimed to evaluate the impact of antiviral therapies and COVID-19 vaccination doses on clinical outcomes in 206 symptomatic MM patients undergoing active treatment across five Italian regions. The majority (90%) received at least one vaccine dose, and 61% were treated with antiviral agents (nirmatrelvir/ritonavir, molnupiravir, or remdesivir). Of the cohort, 90% were vaccinated, with 89% receiving ≥ 3 doses, and 61% received antiviral agents (nirmatrelvir/ritonavir, molnupiravir, or remdesivir). Patients vaccinated with ≥ 3 doses showed significantly reduced infection severity (<i>p</i> = 0.044), hospitalization rates (<i>p</i> = 0.008), and infection resolution time (<i>p</i> = 0.037). Unvaccinated patients without antiviral therapy had a significantly higher mortality rate (<i>p</i> = 0.004). Antiviral therapy, especially when combined with ≥ 3 vaccine doses, further shortened infection resolution time (<i>p</i> = 0.011) but did not significantly affect hospitalization rates or disease severity. This study highlights the critical role of ≥ 3 vaccine doses combined with antiviral therapy in improving COVID-19 outcomes in MM patients, with a reduced infection duration and lower progression to severe disease. Further investigation is required to optimize treatment strategies in this vulnerable population.</p>","PeriodicalId":7325,"journal":{"name":"Advances in Hematology","volume":"2026 ","pages":"5597825"},"PeriodicalIF":0.0,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13269165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}